Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III Low-Density lipoprotein cholesterol goals

American Journal of Cardiology

Volumn 93, Issue 12, 2004, Pages 1481-1486

  Feldman, Theodore ^a   Koren, Michael ^b   Insull Jr , William ^b   McKenney, James ^b   Schrott, Helmut ^b   Lewin, Andrew ^b   Shah, Sukrut ^b   Sidisin, Michelle ^b   Cho, Meehyung ^b   Kush, Debra ^b   Mitchel, Yale ^b  

^a MIAMI RESEARCH ASSOCIATES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; TITRIMETRY;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRACTICE GUIDELINES; RISK FACTORS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 2942574385     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.02.059     Document Type: Article

References (15)

1. van Heek M., France C., Compton D.S., McLeod R.L., Yumibe N.P., Alton K.B., Sybertz E.J., Davis H.R. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharm Exp Ther. 283:1997;157-163
2. van Heek M., Farley C., Compton D.S., Hoos L., Davis H.R. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 134:2001;409-417
3. Gagne C., Bays H.E., Weiss S.R., Mata P., Quinto K., Melino M., Cho M., Musliner T.A., Gumbiner B. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 90:2002;1084-1091
4. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P., Suresh R., Sun S., Veltri E. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 40:2002;2125-2134
5. Ballantyne C.M., Houri J., Notarbartolo A., Melani L., Lipka L.J., Suresh R., Sun S., LeBeaut A.P., Sager P.T., Veltri E.P. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia a prospective, randomized, double-blind trial. Circulation. 107:2003;2409-2415
6. Kerzner B., Corbelli J., Sharp S., Lipka L.J., Melani L., LeBeaut A.P., Suresh R., Mukhopadhyay P., Veltri E. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol. 91:2003;418-424
7. Melani L., Mills R., Hassman D., Lipetz R., Lipka L.J., LeBeaut A.P., Suresh R., Mukhopadhyay P., Veltri E. Efficacy and safety of ezetimibe co-administered with pravastatin in patients with primary hypercholesterolemia a prospective, randomized, double-blind trial. Eur Heart J. 24:2003;717-728
8. Myers G.L., Cooper G.R., Winn C.L., Smith S.J. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program an approach to accurate and precise lipid measurements. Clin Lab Med. 9:1989;105-135
9. Steiner P., Freidel J., Bremmer W., Stein E. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the clinics' methodology. J Clin Chem. 19:1981;850-851
10. Warnick G., Albers J. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res. 19:1978;65-76
11. Stein E., Kreisberg R., Miller V., Mantell G., Washington L., Shapiro D.R. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Arch Intern Med. 150:1990;341-345
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
13. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyörälä K. Prevention of coronary heart disease in clinical practice recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Atherosclerosis. 140:1998;199-270
14. Frost P.H., Havel R.J. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol. 81:(suppl):1998;26B-31B
15. Lamarche B., Moorjani S., Lupien P.J., Cantin B., Bernard P.M., Dagenais G.R., Despres J.P. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation. 94:1996;273-278